Diabetic Ketoacidosis Uncommon With Canagliflozin
Canagliflozin-treated patients with type 2 diabetes have low incidence of serious adverse DKA events.
(HealthDay News) -- For canagliflozin-treated patients with type 2 diabetes, the incidence of serious adverse events of diabetic ketoacidosis (DKA) is low, according to research published online in Diabetes Care.
Ngozi Erondu, M.P.H., from Janssen Research & Development in Raritan, N.J., and colleagues examined the incidence of serious adverse events of DKA among canagliflozin-treated patients with type 2 diabetes. Data were included from 17,596 patients from randomized studies of canagliflozin through May 11, 2015.
The researchers identified serious adverse events of DKA and related events in 12 patients (0.07%). These included 4 (0.07%), 6 (0.11%), and 2 (0.03%) patients treated with canagliflozin 100 and 300 mg, and comparator, respectively. The corresponding incidence rates per 1,000 patient-years were 0.522, 0.763, and 0.238. The majority of those with DKA and related events had a blood glucose of >300 mg/dL, received insulin, and had risk factors such as type 1 diabetes/latent autoimmune diabetes of adulthood.
"DKA and related events occurred at a low frequency in the canagliflozin type 2 diabetes program, with an incidence consistent with limited existing observational data in the general population with type 2 diabetes," the authors write.
The authors were employed by Janssen Research & Development, which funded the study and developed canagliflozin in collaboration with Mitsubishi Tanabe Pharma Corporation.